Cargando…

The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors

The epidermal growth factor receptor (EGFR) and a co-receptor denoted HER2/ERBB2, are frequently overexpressed or mutated in solid tumors, such as carcinomas and gliomas. In line with driver roles, cancer drugs intercepting EGFR or HER2 currently outnumber therapies targeting other hubs of signal tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneider, Marlon R., Yarden, Yosef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820040/ https://www.ncbi.nlm.nih.gov/pubmed/26434585 http://dx.doi.org/10.1038/onc.2015.372

Ejemplares similares

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
por: Uribe, Mary Luz, et al.
Publicado: (2021)

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators
por: Marrocco, Ilaria, et al.
Publicado: (2023)

Myeloid cells: Prime drivers of tumor progression
por: Toh, Benjamin, et al.
Publicado: (2012)

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors
por: Cattaruzza, Fiore, et al.
Publicado: (2023)

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics
por: Sims, Jessica D., et al.
Publicado: (2017)

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
por: Suh, Koung Jin, et al.
Publicado: (2017)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
por: Romaniello, Donatella, et al.
Publicado: (2020)

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis
por: Lindzen, Moshit, et al.
Publicado: (2011)

Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
por: Wu, Yifen, et al.
Publicado: (2015)

A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
por: Gelfo, Valerio, et al.
Publicado: (2016)

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
por: Zhang, Jian, et al.
Publicado: (2014)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Novel agents that downregulate EGFR, HER2, and HER3 in parallel
por: Ferreira, Renan Barroso, et al.
Publicado: (2015)

Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors
por: Pannuti, Antonio, et al.
Publicado: (2018)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

Prognostic significance of HER3 in patients with malignant solid tumors
por: Li, Qin, et al.
Publicado: (2017)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007)

The key roles of cancer stem cell-derived extracellular vesicles
por: Su, Chaoyue, et al.
Publicado: (2021)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Structure and dynamics of the EGFR/HER2 heterodimer
por: Bai, Xue, et al.
Publicado: (2023)

De novo priming: driver of immunotherapy responses or epiphenomenon?
por: Young, Alexander L., et al.
Publicado: (2023)

MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression
por: Kedmi, Merav, et al.
Publicado: (2015)

Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2
por: Bahleda, Rastislav, et al.
Publicado: (2018)

Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
por: Gross, Golda, et al.
Publicado: (2023)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
por: Ariyawutyakorn, Witthawat, et al.
Publicado: (2016)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Non-stem cancer cell kinetics modulate solid tumor progression
por: Morton, Charles I, et al.
Publicado: (2011)

A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
por: Gelfo, Valerio, et al.
Publicado: (2018)

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?
por: Terragni, Rossella, et al.
Publicado: (2014)

Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages
por: You, Daeun, et al.
Publicado: (2023)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
por: Yonesaka, Kimio
Publicado: (2021)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Heptameric Targeting Ligands against EGFR and HER2 with High Stability and Avidity
por: Kim, Dongwook, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lrklfpj46o6jrkrqkvi868e7et